[Federal Register Volume 76, Number 8 (Wednesday, January 12, 2011)]
[Notices]
[Page 2130]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-549]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Inhibitors of the 
Plasmodial Surface Anion Channel as Antimalarials

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i), that the National Institutes of Health, Department 
of Health and Human Services, is contemplating the grant of an 
exclusive patent license to practice the inventions embodied in U.S. 
Provisional Patent Application No. 61/083,000, filed July 23, 2008 [HHS 
Ref. No. E-202-2008/0-US-01], now expired and PCT Patent Application 
No. PCT/US09/50637 [HHS Ref. No. E-202-2008/0-PCT-02] filed July 15, 
2009, which published as WO/2010/011537 on January 28, 2010, both 
applications entitled ``Inhibitors of the Plasmodial Surface Anion 
Channel As Antimalarials,'' and all continuing applications and foreign 
counterparts to Microbiotix, Inc., having a place of business in 
Worcester, Massachusetts. The patent rights in these inventions have 
been assigned to the United States of America.
    The prospective exclusive license territory may be ``worldwide'', 
and the field of use may be limited to ``prevention and treatment of 
malaria in humans.''

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
February 11, 2011 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Kevin W. Chang, PhD, Senior Licensing 
and Patenting Manager, Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
MD 20852-3804; Telephone: (301) 435-5018; Facsimile: (301) 402-0220; E-
mail: [email protected].

SUPPLEMENTARY INFORMATION: The subject technologies are antimalarial 
small molecule inhibitors of the plasmodial surface anion channel 
(PSAC), an essential nutrient acquisition ion channel expressed on 
human erythrocytes infected with malaria parasites. These inhibitors 
were discovered by high-throughput screening of chemical libraries and 
analysis of their ability to kill malaria parasites in culture. Two 
separate classes of inhibitors were found to work synergistically in 
combination against PSAC and killed malaria cultures at markedly lower 
concentrations than separately. These inhibitors have high affinity and 
specificity for PSAC and have acceptable cytotoxicity profiles.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within thirty 
(30) days from the date of this published notice, the NIH receives 
written evidence and argument that establishes that the grant of the 
license would not be consistent with the requirements of 35 U.S.C. 209 
and 37 CFR 404.7.
    Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated exclusive license. Comments and objections submitted to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: January 6, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-549 Filed 1-11-11; 8:45 am]
BILLING CODE 4140-01-P